Trade the BioNTech share!
BIONTECH

Analysis before buying or selling BioNTech shares

Trade the BioNTech share!
BUY   SELL
77% of retail CFD accounts lose money - Plus500.com
 
Chart provided by Tradingview

The shares of the German biotech company BioNTech are among the assets that you can buy or trade in online nowadays. But of course before launching into such an endeavour it is strongly recommended that you know how to complete comprehensive and pertinent analyses of this asset. For this you will need to possess sufficient economical and technical knowledge concerning the asset and this company. We offer our assistance with this by providing data and information on the BioNTech Company with details on its activities, its major competitors on the market and even its recently implemented partnerships. We will also explain how to complete a comprehensive fundamental analysis of this asset.

Elements to consider before selling or buying BioNTech shares

Analysis N°1

Firstly, regarding the activity sector in which the BioNTech Group exercises its biotechnological activities, it is important to take into account the research undertaken by this company and the progress of the different clinical trial phases of its various candidate medications.

Analysis N°2

Obtaining the authorisation for the marketing and sale from international health authorities is also of course a key factor to follow for your fundamental analysis.

Analysis N°3

Still relating to the most important data to take into consideration for this type of analysis, you should concentrate on the strategic partnerships implemented by BioNTech with other companies and notably laboratories too with the objective of obtaining financing in exchange for the commercial authorisation of these completed products.

Analysis N°4

Finally, you should also of course follow closely the activities of BioNTech’s direct competitors, these are the other biotech companies that exercise similar research activities and could therefore exert an influence to a greater or lesser degree on this company’s share price.

77% of retail CFD accounts lose money. This is an advert for trading CFDs on Plus500

General presentation of BioNTech

We shall now examine the BioNTech Group in more detail together with its activities. In fact, a comprehensive knowledge of the precise activities of this company is necessary for you to understand how it can evolve and grow and how its share price could react over the medium or long term. Here therefore is a complete presentation of this group, its activities, and major sources of revenue.

The BioNTech SE Company is a German group that exercises its activities in the biotechnological sector. More precisely this company that is based in Germany concentrates its activities in the immunotherapy segment specifically for the treatment of cancer and other serious illnesses.

This biotech company has therefore developed a wide range of products that use scientific approaches and technological platforms notably including individual product candidates based on the mRNA, chimeric antigen T cell receptors, control immunomodulators, targeted cancer antibodies and small molecules.

It should also be noted that this company offers a large range of diagnostic products and exploratory medicinal services in other therapeutic sectors such as for example infectious diseases, allergies and auto-immune illnesses.

The popularity of the BioNTech Company was recently boosted in 2020 by the implementation of a partnership with the American laboratory Pfizer for the development of the first anti-covid vaccine that received approval and that uses BioNTech’s RNA messenger technology.

The BioNTech Group currently employs around 1,300 people worldwide.

Analysis before buying or selling BioNTech shares
77% of retail CFD accounts lose money. This is an advert for trading CFDs on Plus500

The major competitors of BioNTech

Now that we have examined the BioNTech Company and its precise activities we will shine the spotlight on this group’s activity sectors and its major competitors on the market. In fact, other biotechs and pharmaceutical laboratories are currently in direct competition with the activities of this group and these you should know and follow their announcements, news and financial results closely.

Sanofi 

Of course, one of the major competitors of the BioNTech Group is the Sanofi Group which is a transnational French company. Its activities include pharmaceuticals with certain prescription medications in the sectors of diabetes, rare illnesses, multiple sclerosis and oncology as well as medications for the general public health and its work in the preparation of vaccines.

Regeneron Pharmaceuticals

This is an American biotechnological group that notably produces the Rilonacept treatment. This group from Tarrytown in the State of New York is also working on an anti-covid-19 vaccine.

Moderna Therapeutics 

This well known company is an American biotechnology company that was created in 2010 and is based in Cambridge in the state of Massachusetts. It principal objective is the creation of protein therapies founded upon a ribonucleic acid messenger otherwise known as the RNA Messenger, as with BioNTech. In fact, in 2020, Moderna itself also managed to create a vaccine for Covid-19 which was warmly received by a number of states and countries around the world and in fact obtained various approvals just after its major direct competitors in the United States and the European Union.

Astrazeneca 

This pharmaceutical group is a British company that was created through the merger of the Swedish company Astra and the British laboratory Zeneca in April 1999. The group currently employs over 63,000 people around the world in various activity sectors including research, development, manufacturing, the sale of pharmaceutical products and the provision of services for medical care. The group is active in the areas of diabetes, anaesthesiology, cardiology, infectious diseases, gastroenterology, oncology, neurology and pneumology. It has also created a vaccine against the Covid-19 virus.

CureVac

This is a German biopharmaceutical group which is based in Tubingen. It too is specialised in the development of therapies based on the RNA messenger otherwise known as mRNA. This group notably concentrates its activities in the development of vaccines against infectious diseases and medication for the treatment of cancer and rare diseases and illnesses. The group currently employs nearly 400 people. CureVac has signed a number of partnership agreements with other major companies and organisations such as Sanofi Pasteur, Johnson & Johnson, Eli Lilly and Company, the Coalition for Epidemic Preparedness Innovations and the International Initiative for a vaccine against AIDS. In 2020 the group also perfected a vaccine for the corona virus which was the subject of certain suspicions of poaching which created discord between the United States and Germany.


The major partners of BioNTech

Luckily the BioNTech Group hasn’t just got adversaries on the market, it can count on a number of different significant partners such as those with which it engaged recently in strategic alliances such as the following:

Pfizer 

Firstly, in 2020, the German biotech signed a strategic agreement with the Pfizer Company for the development of a Covid-19 vaccine. The two companies thereby collaborated on the development of an experimental vaccine, which has since been approved, which uses the RNA Messenger technology developed by BioNTech, the BNT162, with the objective of preventing infection from the new corona virus. This collaboration aimed at accelerating the development of this vaccine by benefitting from the resources of both companies. It should be remembered here that these two companies had previously signed a contract in 2018 for the development of a flu vaccine, again based on the mRNA.

Sanofi

Another alliance implemented recently is that between Sanofi and BioNTech. In fact, this first in the pharmaceutical sector was aimed at enabling the French laboratory, after its failure in developing a corona virus vaccine, to produce the vaccine developed by BioNTech and Pfizer. This collaboration was scheduled to begin in early summer 2021 and was aimed at compensating for the production difficulties encountered by the authorised Covid-19 vaccine manufacturers. It was foreseen that Sanofi would be responsible for the last stages in the manufacturing process with the aim of producing over 125 million doses of vaccine for the European Union.

Novartis 

Finally, the last partnership we shall examine that was implemented with Novartis was basically the same as that signed with Sanofi. Novartis signed an initial partnership agreement with BioNTech with the objective of packaging its mRNA vaccine in vials through its aseptic manufacturing site in Stein, Switzerland. It was agreed that, awaiting a definitive agreement, the Swiss pharmaceutical giant would start the production during the second quarter of 2021 and the first vaccine doses would be available from the third quarter.

77% of retail CFD accounts lose money. This is an advert for trading CFDs on Plus500
Positive factors for BioNTech shares
The factors in favour of a rise in the BioNTech share price:

To be able to anticipate how BioNTech's share price will evolve in the coming weeks, months or years, it is necessary to understand how this company can grow or how it can deal with the threats it may face in the future.

To carry out this type of analysis, it is of course necessary to know the main strengths and weaknesses of the company. This is what we propose to discover here in more detail:

Let's start this comparative analysis of BioNTech's strengths and weaknesses by looking at the advantages of this company, which are all arguments in favour of a rise in its share price.

  • First of all, let's remember that BioNTech has benefited from the attention of many investors since 2019, and has experienced a very strong rise in its stock price since then. While in October 2019, when it was first listed, the share price was only 13 dollars, it reached an all-time high of over 450 dollars in August 2021. Although the share price has since corrected slightly downwards, its prospects for further increases remain attractive.
  • One of the major assets of this biotech is of course that it was one of the first to develop an effective vaccine against Covid-19, in collaboration with Pfizer. BioNTech specialises in research into vaccines using messenger RNA, which is one of the effective technologies against the virus.
  • In addition to having been one of the first biotechs to find an effective vaccine against the coronavirus, BioNTech now benefits from a head start over its competitors in this field, as its vaccine is the most widely distributed worldwide and its sales can therefore continue to grow in the months and years to come.
  • The recent development of a child-friendly vaccine to counter the resurgence of the pandemic by opening up vaccination to children over 6 years of age is also an element capable of boosting the company's and Pfizer's performance and sales and could support its share price in the medium term.
  • In addition, BioNTech is currently working, again in partnership with Pfizer, on an adaptation of its vaccine that is more effective against the new variants and could thus be the leader in this field and gain market share rapidly if successful.
  • Finally, still among BioNTech's great assets, we note the trials that the biotech continues to conduct on other treatments and vaccines using messenger RNA and which could make it possible to treat other infectious or other diseases. In addition, thanks to the success of its Covid vaccine, the group could attract the attention of other laboratories and thus obtain more funding.
Negative factors for BioNTech shares
The factors in favour of a drop in the BioNTech share price:

Of course, the BioNTech group does not have only advantages and must also deal with certain weaknesses. It is therefore important to be aware of its weaknesses before you start buying this stock or trading it online. Here is a summary of the main weaknesses of this stock.

  • Firstly, BionTech's share price depends largely on its future sales forecasts. If other Covid-19 vaccines prove effective against the new variants, the company will not be able to meet its expected targets. Furthermore, the development of a specific vaccine against the Omicron variant is not really expected to be cost-effective as the third dose of the existing vaccine already appears to be effective against this variant.
  • Competition, and in particular competition from Moderna, is also an obstacle to BioNTech's growth. Indeed, according to the recent CDC report, it would seem that more people want to choose the more effective Moderna vaccine. If this does not affect BioNTech's sales in the short term, it could still penalise it in the longer term.
The information supplied here is only for indicative purposes and should not be used without the completion of a comprehensive and complete fundamental analysis of this asset notably taking into account exterior data, future publications and announcements and all fundamental events and news that could influence the strengths and weaknesses or make them more or less significant. This information does not in any way constitute recommendations relating to the completion of transactions or a solicitation to buy or sell an asset.

Frequently Asked Questions

What were the last financial results for the BioNTech Group?

The last results published by the BioNTech Group are those for the 2019 financial year. For this year the group declared a turnover of 91,228,000 Euros but its net results were minus 179,172,000 Euros which represent a significant loss. This net loss was due to the fact that the company completed some significant investments that should enable it, over the long term, to generate more profits. Of course, no dividend was paid in 2020 for this financial year.

Which type of analysis should you use for the BioNTech share price?

If you wish to analyse the BioNTech share price you should of course complete a technical analysis as well as a fundamental analysis. A technical analysis uses innovative and up to date charts that enable the display of trend indicators, volatility indicators and strategic thresholds for reversal or acceleration. It is of course important to correctly interpret these indicators and therefore possess a good basic knowledge in order to do so.

Where and how to buy BioNTech shares?

It is of course possible to buy BioNTech shares through certain specific financial placement products notably those specialised in the biotechnologies. It is also possible to use derived financial products that follow the growth of this underlying asset and thereby enable you to speculate online on its price.

77% of retail CFD accounts lose money. You should consider whether you can afford to take the high risk of losing your money. This is an advert for trading CFDs on Plus500